028sek
1,8 %
Date:2025-09-03Time:09:00:01Latest report:Q1-2025List:SpotlightTicker:PHAL
Market Cap:15 msekEnterprise Value:17 msekNet Sales:- msekEarnings:-4,08 msekEmployees:0ISIN:SE0003359710

Ratios

10-year key figure history for PharmaLundensis turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for PharmaLundensis with index and moving average MA50 and MA200.

Stockprice:0,28
MA50:0,32
MA200:0,60
Price/MA200:-53,6 %
RSI (14):49,9
Price/MA50:-12,1 %

Description

PharmaLundensis is a research company. The company's main focus is on the treatment of serious lung diseases. Diseases that the company specializes in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced pulmonary failure. In addition to its main business, technical systems for handling drug emissions are developed. PharmaLundensis has its headquarters in Lund.

Biotechnology